BTEC:SW:SW-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD (USD)

ETF | Others |

Last Closing

USD 7.079

Change

+0.06 (+0.84)%

Market Cap

N/A

Volume

2.81K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.02 (+0.13%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.08 (+0.36%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.17 (+0.61%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

+235.00 (+3.10%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+100.00 (+1.95%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+29.80 (+1.86%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+14.50 (+0.70%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.26 (+0.34%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

+0.40 (+0.35%)

USD 130,595.12B

ETFs Containing BTEC:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.87% 62% D 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.87% 61% D- 62% D
Trailing 12 Months  
Capital Gain 17.98% 76% C+ 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.98% 76% C+ 76% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.19% 52% F 52% F
Dividend Return 3.19% 52% F 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.36% 61% D- 65% D
Risk Adjusted Return 59.47% 52% F 57% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike